EG BioMed is working closely with Taipei Medical University and its three affiliated hospitals to pioneer a revolutionary blood test for the early detection of ten major cancers. These cancers include some of the most common and deadly types, such as breast, colon, rectal, esophageal, stomach, lung, pancreatic, prostate, ovarian, uterine, and liver cancers. This […]
EG BioMed has been closely collaborating with the Health Management Center of Shuang Ho Hospital. During a recent key meeting, Director Dr. Shih-Yu Ko and Deputy Director Dr. Chen enthusiastically praised and endorsed the early detection technology for pancreatic, colorectal, and lung cancers developed by EG BioMed. This groundbreaking technology, which achieves 90%-99% sensitivity, specificity,
The EGBioMed clinical team recently held a important meeting with Dr. Yao-Yu Hsieh, Director of the Department of Hematology/Oncology at Shuang Ho Hospital. Dr. Hsieh, a leading expert in the field, has shown strong support for the recruitment of pancreatic cancer patients and the implementation of a three-month follow-up blood test as part of ongoing
2020/08/07 Breast cancer is the most common cancer among women in Taiwan, but limited by technology, when women have abnormalities in ultrasound and X-rays, they can only find out whether they have cancer through biopsy. Peking University has developed blood breast cancer detection technology, hoping to help Breast cancer screening. On the 6th, Taipei Medical
【TMU】Research and development of accurate blood breast cancer detection technology. Read More »
EG BioMed is proud to announce two groundbreaking advancements in cancer detection: the EG-Breast blood test and the EG-Pancreatic blood test. These innovative tests are designed to identify breast and pancreatic cancers at an early stage without the need for radiation or invasive procedures. Each test requires only a single 10 mL blood sample, which
EG BioMed Unveils Revolutionary Cancer Detection Tests Read More »
Dr. Chih-Ming Su is the Director of Breast Health Care Center, Shuang Ho Hospital, Taipei Medical University, Taiwan. Dr. Chih-Ming Su’s feedback highlights the critical need for more sensitive and reliable blood-based monitoring tools in the management of breast cancer. The EG-Breast Blood Test-P1, with its innovative approach to detecting aberrant methylation in cfDNA, has
According to a report by the National Cancer Institute in July 2021, 1 in 100 newly diagnosed diabetic patients is diagnosed with pancreatic cancer within three years. This finding has been supported by large-scale sample studies published in several medical journals, highlighting the necessity for close monitoring of pancreatic cancer in diabetic patients after diagnosis.
Urgent Need for 3-Year Pancreatic Cancer Blood Tests in New-Onset Diabetes Patients Read More »
Introducing the All-seeing Eye, a groundbreaking technology that detects methylated circulating cell-free DNA released from tumors undergoing apoptosis, necrosis, and secretion into the bloodstream. This innovative approach allows for the non-invasive monitoring of cancer progression by capturing these tumor-derived DNA fragments circulating in the blood. By focusing on the methylation patterns specific to cancer cells,
Discovering the perfect biomarker for cancer progression is like finding a needle in a haystack. But with cutting-edge genomic technologies and a global perspective, we’ve found that needle. Through the use of Illumina methylation arrays, researchers analyzed breast tumor samples from Taiwanese patients and cross-referenced them with data from The Cancer Genome Atlas (TCGA) in
EG BioMed R&D Team Discovers the Key to Revolutionizing Breast Cancer Monitoring Read More »
EG BioMed has achieved a significant breakthrough in the field of pancreatic cancer detection with its innovative EG-Pancreatic Blood Test-E1 technology. This cutting-edge technology has received high praise from international experts and was prominently featured in the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting under Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary. Additionally, it was
